Inogen Inc (INGN) 43.04 $INGN Deloitte's 2015 Technology

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Inogen Inc (INGN) 43.04 $INGN

Deloitte's 2015 Technology Fast 500(TM) Recognizes Inogen as One of the Fastest Growing Companies in North America
GlobeNewswire - Fri Nov 13, 7:30AM CST
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced inclusion in Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. This is the second consecutive year that Inogen has been named to the Fast 500 list.
INGN: 43.04 (-1.38)

Stocks Quietly Reverse Lower; Early Risers: Hackett, LGI Homes
at Investor's Business Daily - Wed Nov 11, 9:28AM CST
Stock slipped out of opening gains and into narrow losses early Wednesday. The Nasdaq dipped 0.1%. The S&P 500 and the Dow Jones industrial average fell into fractional losses. The stock market today rolled out in quiet trade, with bond markets and...
GE: 30.04 (-0.32), LGIH: 30.38 (-0.32), INGN: 43.04 (-1.38), LXFT: 75.36 (-0.99), M: 37.78 (-0.84), HCKT: 19.49 (+0.87), ADT: 34.18 (+0.21), IPGP: 86.42 (+0.50)

Inogen Q3 Earnings In Line, Revenues Beat, 2015 View Up
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:16AM CST
Inogen Inc. (INGN) reported third-quarter 2015 adjusted earnings of 13 cents per share, which were in line with the Zacks Consensus Estimate.
KOOL: 0.30 (-0.29), BABY: 46.80 (-0.02), MASI: 41.96 (+0.36), INGN: 43.04 (-1.38)

Inogen meets 3Q profit forecasts
Automated Insights - Tue Nov 10, 3:11PM CST
GOLETA, Calif. (AP) _ Inogen Inc. (INGN) on Tuesday reported third-quarter profit of $2.7 million.
INGN: 43.04 (-1.38)

Inogen Announces Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 10, 3:05PM CST
- Q3 2015 Revenue Growth of 38.7% Over the Same Period in 2014 -
INGN: 43.04 (-1.38)

Can Inogen (INGN) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 1:10PM CST
Inogen Inc. (INGN) is scheduled to report third-quarter 2015 earnings results on Nov 10.
CLCD: 4.38 (-0.20), OPK: 10.74 (+0.11), INGN: 43.04 (-1.38), ICPT: 168.60 (-5.73)

Inogen Announces Participation in Stifel 2015 Healthcare Conference
GlobeNewswire - Wed Nov 04, 3:06PM CST
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the Company plans to participate in the Stifel 2015 Healthcare Conference in New York, NY.
INGN: 43.04 (-1.38)

Inogen to Announce Third Quarter 2015 Results on Tuesday, November 10, 2015
GlobeNewswire - Tue Oct 27, 3:02PM CDT
Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2015 after market close on Tuesday, November 10, 2015. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
INGN: 43.04 (-1.38)

OxySure (OXYS) Looks to Supercharge Growth
ACCESSWIRE - Tue Oct 27, 7:31AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 27, 2015 / Defibrillators - or AEDs - have become commonplace over the past several years in emergency response situations. According to Markets and Markets, sales of the devices are expected to grow at a 6.9% compound annual growth rate between 2014 and 2019 to reach $12.9 billion, with companies like Medtronic Inc. (NYSE: MDT) and Koninklijke Philips NV (NYSE: PHG) making millions of dollars in revenue for their shareholders.
PHG: 26.53 (+0.18), MDT: 76.45 (+0.21), HNSN: 2.80 (-0.12), CRDC: 0.16 (-0.02), INGN: 43.04 (-1.38)

The Likely Winners in a Medical Device Tax Repeal? Prepare to Be Surprised
Cheryl Swanson, The Motley Fool - Motley Fool - Fri Oct 16, 10:59AM CDT
Medtronic's Twin Cities marathon (Source: Flickr, Creative Commons). If you listen to its critics, the controversial 2.3% Obamacare medical device tax has been a kick in the pants to the entire U.S. medical device industry. In its most recent...
RTIX: 3.71 (-0.04), DXCM: 82.85 (-0.15), MDT: 76.45 (+0.21), INGN: 43.04 (-1.38)

Inogen (INGN) Crumbles: Stock Falls by 5%
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:57AM CDT
Inogen, Inc. (INGN) saw a big move last session, as the company's shares fell by 5% on the day
MASI: 41.96 (+0.36), INGN: 43.04 (-1.38)

Top Stocks AMN Healthcare, Inogen Trip Sell Signals
at Investor's Business Daily - Mon Sep 28, 4:30PM CDT
Leading medical stocks AMN Healthcare Services (AHS) and Inogen (INGN) have enjoyed big price gains this year, but they pierced their 50-day moving averages in heavy volume Monday. Time to sell? With the market in a correction, investors should look...
INGN: 43.04 (-1.38), AHS: 29.58 (+0.18)

Top Stocks ICU Medical, Fidelity Southern Hold Tight
at Investor's Business Daily - Wed Sep 23, 3:18PM CDT
Many stocks in the Spotlight screen have shaped new bases or are on the verge of doing so despite the choppy market. A handful of those -- Abiomed (ABMD), Allegiant Travel (ALGT), MaxLinear (MXL), Palo Alto Networks (PANW) and Skechers (SKX) -- have...
ICUI: 114.31 (+2.83), ABMD: 78.73 (-0.04), LION: 21.91 (+0.20), SKX: 25.12 (-0.25), INGN: 43.04 (-1.38), MXL: 16.17 (+0.28), PANW: 162.25 (+3.50), ALGT: 186.58 (+0.96)

Apple Gets Bullish Call; Nike, Amgen PTs Raised
at Investor's Business Daily - Tue Sep 22, 3:28PM CDT
Apple (AAPL) shares fell Tuesday even after the iPhone maker was given a bullish analyst rating and price target, while Nike's (NKE) and Amgen's (AMGN) price targets were hiked. Goldman Sachs assumed coverage on Apple with a buy rating and gave it a...
CI: 133.77 (+0.28), VA: 36.15 (-0.39), NKE: 122.13 (-1.33), EXPE: 119.82 (-2.71), INGN: 43.04 (-1.38), RHT: 79.82 (+0.73), DD: 66.90 (-0.34), COST: 158.71 (+2.26), AMGN: 157.77 (+3.27), CAT: 69.35 (-1.04), AAPL: 113.66 (-0.52)

3 Top Performing Healthcare Stocks To Hold Forever; 1 Getting Ready To Break-Out For The Long-Term
ACCESSWIRE - Tue Sep 22, 9:27AM CDT
WINDSOR, ONTARIO / ACCESSWIRE / September 22, 2015 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to alert traders about several trade ideas within the very healthy medical device sector.
LMAT: 14.25 (+0.42), SMED: 7.79 (+0.26), INGN: 43.04 (-1.38), IHI: 121.14 (-0.11)

Should You Take Profits In These 4 Leading Stocks?
at Investor's Business Daily - Wed Sep 16, 4:50PM CDT
Four leading stocks have shown tremendous strength in the face of an uncertain market, rising well beyond their buy points. Is it time to take profits? Abiomed (ABMD), Inogen (INGN) and CenterState Banks (CSFL) have given their shareholders a profit...
ABMD: 78.73 (-0.04), INGN: 43.04 (-1.38), CSFL: 15.45 (+0.16), JBLU: 24.92 (-0.10)

Meet The 5 Top-Rated Medical Device Stocks
at Investor's Business Daily - Fri Sep 11, 3:43PM CDT
The recent selloff in drug stocks has dragged down what was once a reliably top-performing sector. Biotech, in particular, seemed permanently lodged in the top 10 of IBD's Industry Group Rankings. But even as biotechs have fallen from the heights, a...
ABMD: 78.73 (-0.04), LMAT: 14.25 (+0.42), INGN: 43.04 (-1.38), VASC: 32.82 (+0.44), CYBX: 69.95 (+0.86)

Inogen Is A Breath Of Fresh Air For Oxygen Patients
at Investor's Business Daily - Tue Sep 08, 5:28PM CDT
The recent sell-off left a lot of newly public companies gasping for air, but shares of portable oxygen concentrator maker Inogen (INGN) are floating even higher. Shares of the Goleta, Calif.-based company have more than tripled since it went public...
ABMD: 78.73 (-0.04), CBM: 48.89 (+0.55), EW: 153.80 (-0.91), INGN: 43.04 (-1.38)

2 Top IPO Stocks Recover Gains After Nasty Sell-Off
at Investor's Business Daily - Mon Aug 24, 3:26PM CDT
Many new issues suffered big declines early Monday along with the overall market . While most IPOs sharply trimmed their losses along with the key market indexes, two stocks showed even healthier recoveries by rising back above their recent buy...
EVHC: 27.03 (-0.57), INGN: 43.04 (-1.38)

Can The Uptrend Continue for Inogen (INGN)?
Zacks Equity Research - Zacks Investment Research - Wed Aug 19, 6:39AM CDT
Can The Uptrend Continue for Inogen (INGN)?
INGN: 43.04 (-1.38)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 42

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 309

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 84

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmmi Receives Extension to Comply with NASDAQ Requirements

Updated Category News Views 64

Farmmi Secures NASDAQ Compliance Extension Farmmi, Inc. (NASDAQ: FAMI), a supplier of agricultural products, has been granted a 180-day extension by NASDAQ to meet its crucial minimum bid price requirement. This extension allows the company until the spring of 2025 to elevate its ordinary share bid price to at least $1.00 for at least ten consecutive business days. The...

Continue Reading
The Neurotechnology Surge: $57B Market by 2034

Updated Category News Views 16

Neurotechnology: The Rising Giant Elbows on the table, let's chew the fat about neurotechnology. The market, dizzyingly projected to soar past USD 57 billion by 2034, is on an explosive trajectory. Folk wiser than us predict an annual growth rate hanging around 14%. This ain't just whispers in coffee shops; it's cold, hard data from DelveInsight’s Market Insights...

Continue Reading
Reviva Pharmaceuticals' New Phase 3 Study for Schizophrenia Drug

Updated Category News Views 99

Reviva Pharmaceuticals' Regulatory Update Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has recently provided an update regarding their journey with brilaroxazine, a novel drug aimed at treating schizophrenia. This news comes after a pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). About Brilaroxazine Brilaroxazine is an innovative...

Continue Reading
Lowe's Reports Strong Earnings Amid Strategic Acquisitions

Updated Category News Views 117

Strong Q2 Earnings Surprise Lowe’s Companies Inc (NYSE: LOW) experienced better-than-expected second quarter earnings, bringing a burst of optimism for investors. The home improvement giant saw its stock increase by approximately 2% shortly after announcing its Q2 financial results. Having recorded solid performance through the quarter, Lowe’s exceeded analysts'...

Continue Reading
Invideo and Kling AI Unite for Game-Changing Visuals

Updated Category News Views 153

Invideo and Kling AI Collaborate to Redefine Video Editing Invideo has recently partnered with Kling AI to introduce an exciting tool known as VFX House. This innovative feature empowers creators with studio-level control for their video projects, offering enhanced capabilities for both marketing and editorial work. Unlocking New Possibilities with VFX House The...

Continue Reading